sibutramine (Meridia, Reductil)

From Aaushi
Jump to navigation Jump to search

Introduction

Withdrawn from US market 10/08/2010[11]

Indications

Contraindications

Dosage

  • start 10 mg PO QD
  • may increase to 15 mg PO QD after 4 weeks
  • max 15 mg QD
  • intermittent therapy (4 month on, 2 months off) may be as effective as continuous therapy[5]

Tabs: 10 mg, 15 mg.

Pharmacokinetics

elimination via liver

Adverse effects

Drug interactions

Laboratory

Mechanism of action

Weight loss of:

More general terms

Additional terms

References

  1. Kaiser Permanente Pharmacy update
  2. Jump up to: 2.0 2.1 Journal Watch 21(5):38, 2001 James WP et al Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 356:2119, 2000 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11191537
  3. Drug Bulletin, Kaiser Permanente, 27:2, 2001
  4. Prescriber's Letter 13(3): 2006 Cytochrome P450 drug interactions Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220233&pb=PRL (subscription needed) http://www.prescribersletter.com
  5. Jump up to: 5.0 5.1 5.2 Journal Watch 21(21):173, 2001 Wirth A & Krause J Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 286:1331, 2001 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11560538
  6. Jump up to: 6.0 6.1 6.2 Prescriber's Letter 9(4):23 2002 FDA MedWatch - Meridia (sibutramine): Early Communication about cardiovascular events http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm191655.htm
  7. Jump up to: 7.0 7.1 Prescriber's Letter 9(8):38 2002
  8. Jump up to: 8.0 8.1 8.2 Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, Hesson LA, Osei SY, Kaplan R, Stunkard AJ. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005 Nov 17;353(20):2111-20. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16291981
  9. Jump up to: 9.0 9.1 Berkowitz RI et al Effects of sibutramine treatment in obese adolescents. A randomized trial. Ann Intern Med 2006, 145:81 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16847290
    Dietz WH What constitutes successful weight management in adolescents? Ann Intern Med 2006, 145:145 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16847296
  10. Jump up to: 10.0 10.1 FDA MedWatch Meridia (sibutramine hydrochloride): Follow-Up to an Early Communication about an Ongoing Safety Review http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm198221.htm11) James WP, - James WP et al Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects N Engl J Med 2010; 363:905-917 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/20818901 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1003114
  11. Jump up to: 11.0 11.1 11.2 11.3 11.4 FDA MedWatch 10/08/2010 Meridia (sibutramine): Market Withdrawal Due to Risk of Serious Cardiovascular Events http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm228830.htm

Database